https://www.ainvest.com/news/elite-pharmaceuticals-27b-anticoagulant-catalyst-earnings-call-investors-2506/ - If the Q4 results beat expectations and the ANDA timeline is clarified, the stock could surge to $1.00–$1.20—a 35%–60% gain.
Market Data 
Markets
AI
